Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286375 | 0.82 | CYP19A1 (0.53) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL13083105 | 0.82 | TDP1 (0.39) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL30645929 | 0.82 | MEN1 (0.42) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL15762161 | 0.82 | MEN1 (0.42) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL26604933 | 0.76 | L3MBTL1 (0.43) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL26604780 | 0.76 | ALDH1A1 (0.38) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL26604835 | 0.76 | TDP1 (0.35) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL27379681 | 0.76 | TSHR (0.38) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL659859 | 0.76 | TSHR (0.45) | TSHRALDH1A1NPC1GAAMAPT | |
| SCHEMBL26604929 | 0.75 | ALDH1A1 (0.40) | TSHRALDH1A1NPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150182496-A1 | MULTIKINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182496-A1 | MULTIKINASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB3, FLT3 | TSHR 2298/4885ALDH1A1 1040/4885NPC1 1306/4885 |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TSHR 866/4885ALDH1A1 2605/4885NPC1 1393/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | TSHR 866/4885ALDH1A1 2605/4885NPC1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.